Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 7/20 | 0.36 |
| ▸ | FPR3 | P25089 | 6/20 | 0.34 |
| ▸ | FPR2 | P25090 | 6/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15171506 | 0.87 | HDAC4 (0.36) | BACE1HCRTR1HCRTR2EGFR | |
| SCHEMBL6878525 | 0.86 | HCRTR1 (0.37) | USP30BACE1FPR3FPR2AAK1 | |
| SCHEMBL12851582 | 0.86 | HCRTR1 (0.37) | USP30BACE1FPR3FPR2AAK1 | |
| SCHEMBL966555 | 0.86 | HCRTR1 (0.37) | USP30BACE1FPR3FPR2AAK1 | |
| SCHEMBL967768 | 0.86 | HCRTR1 (0.37) | USP30BACE1FPR3FPR2AAK1 | |
| SCHEMBL8029927 | 0.86 | BACE1 (0.37) | BACE1HCRTR1HCRTR2BACE2 | |
| SCHEMBL2620015 | 0.86 | BACE1 (0.35) | BACE1FPR3FPR2BACE2 | |
| SCHEMBL18192934 | 0.85 | BACE1 (0.35) | BACE1BACE2 | |
| SCHEMBL3763144 | 0.85 | BACE1 (0.35) | BACE1BACE2 | |
| SCHEMBL18192834 | 0.85 | BACE1 (0.35) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2011005738-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009395-A1 | BACE INHIBITORS | BACE1, BACE2, APP | USP30 1601/4885BACE1 1/4885FPR3 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.